Non-biological factors in day to day variation of heparin requirements

Fennerty, A.G.; Levine, M.N.
October 1989
BMJ: British Medical Journal (International Edition);10/21/89, Vol. 299 Issue 6706, p1012
Academic Journal
Reports the non-biological factors in daily variation of heparin requirements. Maintenance of the partial thromboplastin time; Monitor on the pressure infusion devices; Variables in the delivery and monitoring of a heparin infusion.


Related Articles

  • PTT monitoring schedule. Koepke, John // MLO: Medical Laboratory Observer;Dec98, Vol. 30 Issue 10, p10 

    Answers a query about the use of partial thromboplastin time (PTT) to monitor unfractionated heparin treatment. Recommended weight-based dose of unfractionated heparin; Difference between low molecular weight heparin and unfractionated heparin; Reason for the need to obtain a baseline PTT prior...

  • Establishing a Therapeutic Range for Heparin Therapy. Brill-Edwards, Patrick; Ginsberg, Jeffrey S.; Johnston, Marilyn; Hirsch, Jack // Annals of Internal Medicine;7/15/93, Vol. 119 Issue 2, p104 

    Presents a study that compared two methods of determining a therapeutic range of activated partial thromboplastin time (aPTT) results. Effect of different aPTT reagents on the therapeutic range; Comparison of regression lines describing the relation between the aPTT and heparin levels for Dade...

  • Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia. Hursting, Marcie J.; Lewis, Bruce E.; Macfarlane, Donald E. // Clinical & Applied Thrombosis/Hemostasis;Jul2005, Vol. 11 Issue 3, p279 

    Argatroban, a direct thrombin inhibitor used for thromboprophylaxis or treatment in heparin-induced thrombocytopenia (HIT), is routinely monitored using the activated partial thromboplastin time (aPTT) yet also prolongs the international normalized ratio (INR). Peritransitional INRs, aPTTs,...

  • Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin. Kalaska, Bartlomiej; Kaminski, Kamil; Sokolowska, Emilia; Czaplicki, Dominik; Kujdowicz, Monika; Stalinska, Krystyna; Bereta, Joanna; Szczubialka, Krzysztof; Pawlak, Dariusz; Nowakowska, Maria; Mogielnicki, Andrzej // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Protamine, the only registered antidote of unfractionated heparin (UFH), may produce a number of adverse effects, such as anaphylactic shock or serious hypotension. We aimed to develop an alternative UFH antidote as efficient as protamine, but safer and easier to produce. As a starting material,...

  • APTT in Heparinized Plasma: Influence of Reagent, Acute-Phase Reaction, and Interval Between Sampling and Testing. Strekerud, Finn G.; Abildgaard, Ulrich // Clinical & Applied Thrombosis/Hemostasis;Fall1996, Vol. 2 Issue 4, p250 

    Plasma samples from 10 healthy persons and 10 patients with acute-phase reaction were heparinized in vitro to obtain 0.00-0.70 U/ml. The activated partial thromboplastin time (aPTT) was then determined, using an optical method (Automated Coagulation Laboratory) and four reagents (actin,...

  • Differential Effects of Unfractionated Heparin and Low-Molecular-Weight Heparins on Tissue Thromboplastin Inhibition Test. Gerbutavicius, Rolandas; Iqbal, Omer; Messmore, Harry; Hoppensteadt, Debra A.; Demir, Muzaffer; Khan, Erum; Bacher, Peter; Fareed, Jawed // Clinical & Applied Thrombosis/Hemostasis;Oct2000, Vol. 6 Issue 4, p190 

    Circulating anticoagulants are endogenously produced substances that interfere with in vitro tests of coagulation like activated partial thromboplastin time (APTT). and cause prolongation of the clotting times. Evaluation of the abnormal APTT involving various factor assays and mixing studies...

  • The influence of acetaldehyde and glycosaminoglycans upon Factor Xa- and Factor X-deficient plasma. Brecher, Arthur S.; Hommema, Eric L. // Canadian Journal of Physiology & Pharmacology;Sep2002, Vol. 80 Issue 9, p879 

    The comparative effects of glycosaminoglycans and acetaldehyde (AcH) - glycosaminoglycan (GAG) mixtures upon Factor Xa- (FXa) and Factor X-deficient plasma (FXDP) have been studied by activated partial thromboplastin time (APTT) studies. Heparin at 0.025, 0.030, 0.04, and 0.05 U statistically...

  • Heparin-tissue Factor Pathway Inhibitor Complexes: Anticoagulant and Pharmacokinetic Properties. Tze-Chein Wun; Palmier, Mark O. // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p179 

    Exogenous addition of full-length tissue factor pathway inhibitor (FL-TFPI) to plasma caused a greater prolongation of prothromin time (PT) than activated partial thromboplastin time (APTT). In contrast, heparin elicited a greater prolongation of APTT than PT. These results suggest that FL-TFPI...

  • aPTT in Heparinized Patients: Influence of the Interval Between Sampling and Testing. Rachakonda, Vikrant; Rachakonda, Leelanand; Belliveau, Robert R. // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p213 

    Activated partial thromboplastin times(aPTTs) from, 29 whole blood samples were drawn from patients receiving unfractionated heparin through a constant intravenous drip. Three aPTTs were determined for each whole blood sample. The first aPTT was performed on a separate portion of the original...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics